|Title||Cancer pharmacogenomics: early promise, but concerted effort needed.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||McLeod, Howard L.|
|Date Published||2013 Mar 29|
|Keywords||Antineoplastic Agents, Biomarkers, Pharmacological, Biomarkers, Tumor, Drug Design, Female, Genetic Markers, Genome, Human, Germ-Line Mutation, Humans, Molecular Targeted Therapy, Neoplasms|
The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cellular signaling pathways in tumors. This in turn has led to the development of targeted therapies, with somatic mutations serving as genomic predictors of tumor response and providing new leads for drug development. There is also a realization that germline DNA variants can help optimize cancer drug dosing and predict the susceptibility of patients to the adverse side effects of these drugs-knowledge that ultimately can be used to improve the benefit:risk ratio of cancer treatment for individual patients.
|Original Publication||Cancer pharmacogenomics: early promise, but concerted effort needed.|
|PubMed Central ID||PMC3900028|
|Grant List||R01 HL110380 / HL / NHLBI NIH HHS / United States |
R01HL110380 / HL / NHLBI NIH HHS / United States
R01 CA161608 / CA / NCI NIH HHS / United States
UL1 RR025747 / RR / NCRR NIH HHS / United States
P01CA142538 / CA / NCI NIH HHS / United States
P01 CA142538 / CA / NCI NIH HHS / United States
Cancer pharmacogenomics: early promise, but concerted effort needed.